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Abstract
The molecular mechanisms leading to the transformation of anaplastic lymphoma kinase negative (ALK−) anaplastic large
cell lymphoma (ALCL) have been only in part elucidated. To identify new culprits which promote and drive ALCL, we
performed a total transcriptome sequencing and discovered 1208 previously unknown intergenic long noncoding RNAs
(lncRNAs), including 18 lncRNAs preferentially expressed in ALCL. We selected an unknown lncRNA, BlackMamba, with
an ALK− ALCL preferential expression, for molecular and functional studies. BlackMamba is a chromatin-associated
lncRNA regulated by STAT3 via a canonical transcriptional signaling pathway. Knockdown experiments demonstrated that
BlackMamba contributes to the pathogenesis of ALCL regulating cell growth and cell morphology. Mechanistically,
BlackMamba interacts with the DNA helicase HELLS controlling its recruitment to the promoter regions of cell-architecture-
related genes, fostering their expression. Collectively, these findings provide evidence of a previously unknown tumorigenic
role of STAT3 via a lncRNA-DNA helicase axis and reveal an undiscovered role for lncRNA in the maintenance of the
neoplastic phenotype of ALK−ALCL.
Introduction
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous
group of tumors, which include 29 different subtypes
according to the World Health Organization (WHO).
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lymphomas (ALCL) are characterized by distinct histo-
pathological and clinical features. ALCL are stratified based
on the presence of anaplastic lymphoma kinase (ALK)
translocations [1–4]. Clinically, systemic ALK−ALCL dis-
plays a poor response to therapy and inferior survival
compared with ALK+ALCL [4–9]. Within ALK−ALCL,
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distinct subsets have been described [7]. ALK−ALCL share
unique transcriptional signatures [6, 10] and can be further
classified using recurrent genomic abnormalities including
JAK1/STAT3 mutations, DUSP22 or TP63 translocations,
loss of TP53 and PRDM1/BLIMP1, and aberrant expression
of ERBB4 [3, 4, 11]. However, the molecular mechanisms
leading to ALK−ALCL transformation, maintenance, and
immune evasion remain quite elusive. Hyperactivation of
STAT3 is documented in about 40–50% of ALK− ALCL
[3], and contributes to the tumorigenesis and maintenance
of STAT3+ ALCL via canonical gene regulation [3, 12] a
paradigm shared by many human cancers. However, new
findings suggest that STAT3 can also contribute to cancer
tumorigenesis by regulating long noncoding RNA
(lncRNA) [13, 14].
LncRNAs are transcripts, longer than 200 nucleotides,
often display an intron–exon organization, and share close
similarities to protein-coding genes. They have pleotropic
properties, controlling gene expression, protein stability,
localization and function, and cell identity [15]. Unbiased
genome-wide analyses discovered thousands of lncRNAs,
whose number outnumbers those of protein-coding RNAs.
More than 8000 lncRNAs are aberrantly expressed in can-
cer, making these genes ideal tumor-specific biomarkers
and putative targets for therapeutic interventions [16].
Remarkably, lncRNAs can shape the T-cell compartment
and modulate the adaptive immune system [17]. Detectable
lncRNAs are often located within the neighborhood of
lineage-specific mRNA [17], and their dynamic expression
is cell/stage-specific regulated [18] and linked to cell dif-
ferentiation and identity [19]. Indeed, IFNG-AS1, linc-
Ccr2–59AS, Th2 LCRR, and GATA3-AS1 are associated
with distinct T-helper 1 (Th1) or Th2 phenotypes [20–22]
while lincRNA-MAF-4 promotes T-lymphocyte differ-
entiation by interacting with chromatin modifiers LSD1 and
EZH2 via MAF [19]. Conversely, their oncogenic con-
tributions in T-cell lymphoma remain poorly elucidated and
their contribution to the ALCL phenotype remains unex-
plored [23–25].
Here, by performing deep expression profiling in con-
junction with de novo transcriptome assembly, we dis-
covered a panel of previously unknown lncRNAs of ALCL.
We focused on a chromatin-associated lncRNA, selectively
expressed by ALK− ALCL lymphoma, named Black-
Mamba. Mechanistically, BlackMamba is regulated via
STAT3 and its expression is required to sustain proliferation
and clonogenicity of ALK− ALCL through the transcrip-
tional regulation and the functional control of the lymphoid
helicase HELLS. These findings provide new evidence on
the mechanisms leading to STAT3-mediated ALCL trans-
formation and foster the implementation of STAT3 target
therapies for these lymphomas.
Materials and methods
Tissue samples
Fresh and viable cryopreserved cells were isolated from
diagnostic/relapsed primary lymphoma biopsies. Diagnoses
were assigned according to the WHO classification. Tissues
used for NGS analyses were selected for their high tumor
cell content (>50%). All studies were approved through
institutional human ethics review boards, and patients pro-
vided written informed consent in accordance with the
Declaration of Helsinki.
Cell growth, colony formation assays, and cell
division
For cell growth assays, cells were washed with phosphate-
buffered saline seeded at 2.5 × 105 cells/ml and treated with
drugs. Viable cells were counted by trypan blue exclusion.
Colony formation assays were performed as previously
described [26].
Cell division was evaluated using 5 μM of carboxy-
fluorescein succinimidyl ester (CFSE) fluorescent dye fol-
lowing the manufacturer’s instructions (ab113853, Abcam).
The fluorescence was read by FACSCanto II instrument
after 6 or 9 days and data were analyzed using BD
FACSDiva Software (BD).
Analysis of mRNA stability
Actinomycin D was used to inhibit nascent RNA synthesis.
MAC2A, TLBR-1, and TLBR-2 cells (5 × 105 cells/ml)
Fig. 1 ALCL samples expressed a restricted set of aberrantly
activated previously unknown lncRNAs. a Schematic representation
of human samples used to perform directional RNA sequencing.
b Bioinformatic pipeline for the discovery of previously unknown
lncRNAs. c Density plot for transcript length shows shared pattern
between previously unknown and known lncRNAs compared with
protein-coding genes, which are much longer. d Coding Potential
Score obtained from GENEID shows that previously unknown
lncRNAs and known lncRNAs have comparable and lower average
coding potential than do protein-coding genes. e Comparing pre-
viously unknown lncRNAs against all transcripts with at least two or
more exons show a greater number of exons for the protein-coding
genes. f Unsupervised analysis of previously unknown lncRNAs
profile across normal T-cell lymphocytes and ALCL primary samples.
g Flowchart for the discovery of BlackMamba in ALK− ALCL sam-
ples. h Schematic representation of locus, structure, and aligned reads
of BlackMamba. Numbers represent the length (bp) of exons and
introns (gray). Sashimi plots of representative ALK− and AL+ ALCL
samples were generated by Integrative Genomics Viewer software.
The genomic coordinates are measured along the horizontal axis and
the RPKM (Reads Per Kilobase per Million mapped reads) values up
the vertical axis. qRT-PCR analysis of BlackMamba in a validation set
of ALCLs samples (i) and in a panel of cell lines (j).
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were treated with actinomycin D or DMSO (5 μg/ml,
Sigma-Aldrich) for 2, 4, 8, 16, and 24 h and collected for
RNA isolation.
siRNA transfection
FEPD, MAC2A, TLBR-1, and TLBR-2 cells (1 × 106) were
transfected with 5 or 10 pmoli siRNA using the Cell Line
Nucleofector Kit SF and Amaxa 4D Nucleofector (program
FI115 for FEPD and MAC2A, DS-130 for TLBR-2 and for
TLBR-1). Twenty-four hours after transfection, cells were
harvested and plated 2.5 × 105 cells/ml. For STAT3, we
used a Silencer Select Validated siRNA ID:s743 (Ambion,
Life Technologies); for BlackMamba we used three differ-
ent Silencer Selected siRNAs (Ambion, Life Technologies)
(Supplementary Table 1).
Luciferase assay
MAC2A and TLBR-2 cells (1 × 106) were transfected with
0.4 µg of reporter pGL3-luciferase plasmids using the Cell
Line Nucleofector Kit SF and 4D Amaxa Nucleofector
(program FI115 for MAC2A, DS-130 for TLBR-2).
Twenty-four hours after transfection, cells were har-
vested and luciferase activity was measured using the Dual-
Luciferase Reporter Assay System (Promega) in a GloMax
Discover Luminometer (Promega) according to the manu-
facturer’s instructions. For each sample, firefly luciferase
activity was normalized on Renilla luciferase activity and
transactivation of the various reporter constructs was
expressed as fold induction on empty vector (pGL3-basic or
pGL3-promoter) activity.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed as previously described
[27]. Chromatin was precipitated with antibodies against
H3K4me3 (Abcam-ab8580), H3K4me1 (Abcam-ab8895),
H3K27Ac (Abcam-ab4729), RNA polymerase II STD
repeat YSPTSPS ((phospho S5) (Abcam – ab5408), STAT3
(124H6 Mouse mAb#9139), HELLS (H-4, sc-46665 Santa
Cruz), or IgG (as negative control). For each experiment, a
chromatin amount corresponding to 0.5% of chromatin used
for immunoprecipitation was kept as input control. Each
qRT-PCR value was normalized over the appropriate input
control and reported in graphs as % of input (qRT-PCR
value/input value × 100).
RNA immunoprecipitation (RIP)
RIP was performed as described by Abcam RIP protocol.
The precleared lysate was incubated for 2 h with 6 μg of
antibodies specific for HELLS (sc-46665, Santa Cruz Bio-
technology, Inc.) or with IgG as negative control. All
experiments were repeated at least three times.
Quantitative PCR (qRT-PCR)
One microgram of total RNA was reverse transcribed using
RT (iScript, Biorad). The amplified transcript level of each
specific gene was normalized on CHMP2A housekeeping.
ΔΔCt quantification method was used for RT-qPCR
analyses.
The list of primers used is provided in Supplementary
Table 2.
Western blot
Western blot analysis was performed using standard techni-
ques [3]. The primary antibodies were: STAT3 (124H6
Mouse mAb#9139, 1:1000 Cell signaling Technology),
pSTAT3 (Tyr705, D3A7 Rabbit mAb#9145, 1:1000 Cell
signaling Technology), STAT5 (D2O6Y Rabbit mAb#94205,
1:1000 Cell signaling Technology) pSTAT5 (Tyr694, Rabbit
mAb#9351, 1:1000 Cell signaling Technology), ALK (D5F3
Rabbit mAb#3633, 1:1000 Cell signaling Technology),
pALK (Tyr1604, Rabbit mAb#3341, 1:1000 Cell signaling
Technology), β-Actin (sc-47778, 1:1000 Santa Cruz
Biotechnology, Inc.), and HELLS (sc-46665, 1:1000 Santa
Cruz Biotechnology, Inc.). All secondary antibodies (rabbit
and mouse) were HRP-conjugated (GE Healthcare) and
diluted 1:5000.
Immunofluorescence
Immunofluorescences were performed as previously descri-
bed [28].
Statistical analyses
Statistical analyses for identification and the analysis of
lncRNAs are described in Supplementary methods.
Fig. 2 BlackMamba is a previously unknown long noncoding RNA
in ALK− ALCL subset. a Schematic representation of BlackMamba
genomic locus showing the position and the level of histone mod-
ifications of the putative promoter and the representation of TSS
region. Luciferase activity of overlapping fragments into pGL3 vector
(b) and luciferase activity of P4 fragment into pGL3-promoter vector
(c). Data are represented as normalized ratio of firefly-Renilla luci-
ferase activities and are expressed as mean values ± SD (n= 3). **p ≤
0.01. ChIP quantitative qRT-PCR detection of H3K27ac (d),
H3K4me3 (e), and phospho- S5-RNA-polymerase II (f) on P4 frag-
ment in a panel of cell lines. GAPDH promoter was used as CTR+
whereas, BlackMamba region +33,459 bp (BlackMamba) and a non-
coding intergenic region (CTR−) served as negative controls. The
values represent mean ± SEM (n= 3). **p ≤ 0.01.
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Statistical analyses were performed using GraphPad
Prism Software (GraphPad). Statistical significance was
determined using the Student’s t test. Each experiment was
replicated multiple time (>3 up to 6).
Results
ALCL express a large pool of previously unknown
lncRNAs
To define lncRNAs preferentially associated with ALCL,
we performed high coverage and directional RNA sequen-
cing (RNA-Seq) of 21 ALK+ ALCL and 16 ALK− ALCL
primary samples. We included normal T-lymphocytes,
corresponding to different stages of differentiation and 10
ALCL cell lines (Fig. 1a and Supplementary Table 3).
Firstly, to confirm the appropriateness of pathological
samples within our discovery set, we used a 3-gene model
classifier (TNFRSF8, BATF3, TMOD1), proven to accu-
rately define ALK+ and ALK− ALCL (Supplementary
Fig. 1A) [6]. A principal component analysis based on
canonical coding gene expression further resolved the dis-
covery cohort into distinct clusters corresponding to normal
T-cell and ALCLs (Supplementary Fig. 1B); the latter group
was further stratified into two distinct subgroups, largely
represented by ALK+ and ALK− ALCL samples (Supple-
mentary Fig. 1C).
Next, we executed a de novo transcriptome analysis of
the aligned primary tumor samples [29], which identified
106,014 new transcripts. Applying filtering cutoffs based on
transcript length, exon count, and coding potential (based
on cross-species comparisons), we discovered 1208 pre-
viously unknown ALCL-specific lncRNAs (Fig. 1b). These
lncRNAs showed transcript length >200 bp (a canonical
lncRNAs feature), a stringent number of exons n= 2 for
conserved spliced transcripts (Fig. 1c, d), and they
displayed low coding potential compared to canonical
coding RNAs (Fig. 1e).
Next, we identified a set of lncRNAs significantly
overexpressed in ALCL samples (18/352) by unsupervised
analysis (Supplementary Table 4). Even if this set was not
able to fully discriminate ALK+ and ALK− ALCL, these
novel lncRNAs were found to be significantly over-
expressed in ALCL compared with normal T-lymphocytes
(Fig. 1f and Supplementary Fig. 1D, E). Then we restricted
the analysis to lncRNAs expressed in at least 20% of ALCL
samples (five or more samples), this analysis led to the
discovery of a pool of 14 lncRNAs (FDR < 0.05) (Fig. 1g).
Since the deregulated STAT3 signaling is oncogenic in
ALCL [3, 12], we then searched for canonical STAT3
binding sites within putative promoter regions of these
previously unknown lncRNAs (Fig. 1g). We identified the
lncRNA XLOC_043524 only, which we named
BlackMamba.
BlackMamba is a nonannotated lncRNA located on
q26.3 of chromosome 10, predicted to be transcribed from
the minus strand, with an estimated transcript length of
70,292 bp (Fig. 1) and with half-life of ~4 h (Supplementary
Fig. 2a–d). BlackMamba is composed of three exons,
lacking alternative isoforms. Within the discovery cohort, 9/
16 ALK− ALCL (56%) and 1/21 ALK+ ALCL (4.7%)
expressed detectable levels of BlackMamba. The pre-
ferential expression of ALK− ALCL was further confirmed
in an independent set of 15 ALCLs and 9 PTCLs, and no
detectable transcripts were seen in a cross-validation cohort
of healthy donor resting and activated PBMCs (Fig. 1i and
Supplementary Table 5). When we extended this analysis to
a panel of T-cell lines, we confirmed that BlackMamba
expression was consistently detectable in ALK− ALCL and
breast implanted associated (BIA)-ALCL cell lines, albeit
with variable levels of expression, with TLBR-1 and TLBR-
2 expressing the highest levels. Very low transcripts were
detected in ALK+ ALCL (L82 and Karpas299), systemic
and cutaneous ALK-ALCL (FEPD, Mac1), and in cuta-
neous T-cell lymphoma MJ, while T-ALL lines (CUTLL1,
KOPT-K1, and Jurkat), and mycosis fungoides HUTL-78
cells were negative (Fig. 1j).
BlackMamba is a promoter-associated lncRNA
transcriptionally regulated by STAT3
To explore the mechanism(s) which regulates the expres-
sion of BlackMamba, we investigated the genomic elements
responsible for its transcription. H3K4me3 profile by ChIP-
seq in ALK− ALCL cell lines and patient-derived tumor
xenograft (PDTX) (Belli) lines showed a high-density
profile within a 2000 bp region, spanning the putative
transcription start site (TSS) (Fig. 2a). These data are in
agreement with a relatively high level of H3K4Me3 (but not
Fig. 3 STAT3 regulates BlackMamba expression. a STAT3 ChIP-
sequencing analysis (top panel) and ATAC-sequencing analysis (bot-
tom panel) along BlackMamba locus in ALK− ALCL cell lines and
PDTX (Belli ALK− ALCL and IL89 BIA-ALCL). b qRT-PCR ana-
lysis of BlackMamba expression after 24 h of treatment with 1 μM of
ruxolitinib or 2 μM of INCB039110. The values represent mean ± SD
(n= 3) *p ≤ 0.05; **p ≤ 0.01. ChIP qRT-PCR detection of: (c) STAT3
antibody on P1 fragment, (d) Phospho-5 s RNA Polymerase II, and
(e) anti-H3K27ac antibodies on P4 fragment of BlackMamba in ALK−
ALCL cell lines treated for 24 h with 1 μM of ruxolitinib. Black-
Mamba region +33,459 bp (BlackMamba) was used as a negative
control. ATF3 promoter was used as positive control for STAT3
binding, whereas GAPDH promoter was used as positive control for
d, e. The values represent mean ± SEM (n= 3). **p ≤ 0.01; *p ≤ 0.05.
f qRT-PCR analysis of BlackMamba in two different regions (+438 bp
and +33,459 bp) in ALK− ALCL cells after transfection with specific
STAT3-siRNA (96 hours). CD30 was used as positive control. The
values represent mean ± SD (n= 3); *p ≤ 0.05; **p ≤ 0.01.
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of H3K4Me1) within the same region in ENCODE (in
several cell lines), suggesting that BlackMamba is likely to
be a promoter-associated gene rather than an enhancer-
associated RNA. To elucidate the promoter region of
BlackMamba, we then cloned multiple DNA fragments
upstream of a luciferase reporter cassette corresponding to a
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region of 2000 bp (P1-P5), spanning from −811 to +1076
bp of the BlackMamba TSS (Fig. 2a). High luciferase sig-
nals were observed with the segment spanning
from −459 bp to −90 bp (P4) in both MAC2A and TLBR-2
(Fig. 2b). By cloning P4 in an “enhancer-like” position
downstream to the reporter gene, we demonstrated that this
segment did not act as an enhancer (Fig. 2c). We next show
that the H3K27Ac and H3K4Me3 marks were enriched in
two ALK− ALCL lines but not in BlackMamba negative
CUTLL1 line (Fig. 2d, e). Likewise, the RNA-Pol II was
found to be actively recruited on the P4 element only in the
ALK− ALCL cells (Fig. 2f).
ALK+ and ALK− ALCLs can be addicted to JAK-STAT
signaling pathway, and the loss of STAT3 signaling impairs
their growth and survival [3, 12]. Because we initially
predicted that BlackMamba had a canonical binding site for
STAT3, we tested whether STAT3 could bind to the
BlackMamba promoter. By STAT3 ChIP -Seq, ALK− cell
lines and PDTX displayed multiple STAT3 peaks in close
proximity to the P1 or bs_II and bs_III sites of BlackMamba
(Fig. 3a). These regions corresponded to accessible, active
chromatin sites by ATAC-seq. (Fig. 3a). To test the
BlackMamba dependence on the transcriptional activity of
STAT3, we tested the level of STAT3 phosphorylation in a
panel of cell lines (Supplementary Fig. 3A). Next, STAT3+
ALK− ALCL cells were treated with a JAK1/2 (ruxolitinib)
or a selective JAK1 inhibitor (INCB039110), demonstrating
that after 24 h of treatment the mRNA expression of
BlackMamba was downregulated (Fig. 3b). Consistent with
ChIP-seq data, STAT3 was significantly enriched on iden-
tified regions of BlackMamba (Fig. 3c). Moreover, the JAKi
treatment resulted in the specific inhibition of RNA-Pol II
binding, reduced transcriptional activity and the con-
comitant modulation of H3K27Ac marks (Fig. 3d, e).
Lastly, since the pharmacological inhibition of JAK/STAT
can elicit a plethora of targets and trigger alternative events,
we evaluated the expression of BlackMamba upon silencing
of STAT3 by specific siRNA. Having first demonstrated
that STAT3-siRNA could effectively reduce STAT3
expression (Supplementary Fig. 3B) and its canonical tar-
gets (i.e., CD30, Fig. 3f). we confirmed that the loss of
STAT3 was associated with the downregulation of Black-
Mamba (Fig. 3f).
Remarkably, although the expression of BlackMamba
was barely detectable in ALK+ALCL, the selective inhibi-
tion of ALK signaling (crizotinib) led to the downregulation
of BlackMamba (Supplementary Fig. 3C).
Collectively, these data demonstrate that STAT3 reg-
ulates the expression of BlackMamba, independently from
its upstream activators.
BlackMamba is required for active proliferation and
clonogenicity of ALK− ALCL cells
To test the biological properties of BlackMamba, we
silenced its expression using two different approaches: a
transient siRNA transfection and a doxycycline inducible
shRNA. Because BlackMamba is a large gene (~70 kb), we
targeted different regions (Supplementary Fig. 4A and
Supplementary Table 2). We found two independent
shRNAs that effectively reduced its expression after dox-
ycycline induction in MAC2A (−50% for each shRNAs)
without affecting top-scoring off-targets significantly
(Supplementary Fig. 4B). Both shRNA#2 and #6 could
effectively knockdown (KD) the lncRNA in TLBR-2,
although with different potency (−30%, shRNA#2 and
−60%, shRNA#6) (Fig. 4a). Next we studied the cellular
localization of BlackMamba at steady state, demonstrating it
was enriched in the nucleus and strongly associated to the
chromatin fraction, suggesting a putative role in chromatin
organization and gene expression regulation (Fig. 4b and
Supplementary Fig. 4C).
Functionally, the KD of BlackMamba resulted in a dose-
dependent cell growth inhibition (Fig. 4c and Supplemen-
tary Fig. 4D, E), in the absence of an increased rate of
apoptosis (Supplementary Fig. 4F). This phenotype was
reproducibly detected in shRNA#6-treated ALCL cells,
although significant shRNA#2 mediated changes were
observed only in MAC2A cells, which expressed lower
levels of mRNA (Supplementary Fig. 4G). Next we
demonstrated a delayed cell division in BlackMamba KD
cells (Fig. 4d and Supplementary Fig. 4H, I), and an
impaired ALCL lymphoma colony formation (Fig. 4e).
Conversely, the growth and survival in control K562
(chronic myeloid leukemia) and CUTLL1 KD cell lines
Fig. 4 Loss of BlackMamba leads to impaired cell proliferation and
clonogenicity of ALK− ALCL cells. a qRT-PCR analysis of Black-
Mamba expression after 6 days of doxycycline treatment in MAC2A
and TLBR-2 cells. b Relative expression of BlackMamba in cyto-
plasm, nucleus, and chromatin fraction of ALK− ALCL cell lines
(average of three independent experiments ± S.D.) One-tailed t-test.
*p ≤ 0.05. c Growth curve of MAC2A and TLBR-2 expressing pLKO-
shRNA BlackMamba after induction with doxycycline. Each data
point represents the mean ± S.D. (n= 3). One-tailed t-test. *p ≤ 0.05;
**p ≤ 0.01. d The histograms show the fluorescent intensity of CFSE-
labeled TLBR-2 and MAC2A expressing pLKO-shRNA BlackMamba
(9 days of treatment). Each data point represents the mean ± S.D. (n=
3). One-tailed t-test. *p ≤ 0.05; **p ≤ 0.01. e Histogram shows
methylcellulose colony formation of pLKO-shRNAs BlackMamba
expressing cells pretreated with doxycycline for 6 days. Colonies were
counted on day 10, after plating. Each data point represents the mean
± S.D. (n= 3). f The upper panel shows the percentage of poly-
nucleated cells in at least 100 cells stained with May–Grunwald
Giemsa (6 days after doxycycline induction). Each data point repre-
sents the mean ± S.D. (n= 3). *p ≤ 0.05; **p ≤ 0.01. The lower panel
shows the polynucleated cells in TLBR-2. The scale bar represents
100 μm. g FISH analysis of chromosome 17 centromere in pLKO-
shRNAs BlackMamba expressing TLBR-2 and MAC2A cells (6 days
of doxycycline induction). The scale bar represents 10 μm.
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were not affected (Supplementary Fig. 4J). Interestingly, the
cytological inspection of May–Grunwald Giemsa stained
ALK−ALCL cells upon BlackMamba KD showed an
increased number of polynucleated cells (Fig. 4f and Sup-
plementary Fig. 4K), with a polyploid DNA content by
partial FISH-based karyotyping (Fig. 4g).
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Lastly, since cytokinesis requires an appropriate
cytoskeleton organization, we investigated the cytoske-
leton architecture of BlackMamba silenced cells. As actin
filaments are major components of the contractile struc-
ture that guide cytokinesis in eukaryotes [30], we exam-
ined the cellular cytoskeleton using phalloidin staining of
actin filaments. We found that after BlackMamba KD,
cells lose actin polarization and have a displacement of
filaments from their membrane localization, supporting its
role in cytoskeleton reorganization and cytokinesis
(Fig. 5a). This hypothesis is supported by the transcrip-
tional changes observed after RNA sequencing in Black-
Mamba KD (59 downregulated genes and 61 significantly
upregulated genes, ≥2-fold and FDR < 0.05, Fig. 5b and
Supplementary Table 6) where top-scored genes modu-
lated (i.e., RGS1, CCL22, CCL17, PAK2, RHOU) epi-
tomize by the modulation of actin cytoskeleton, integrin-
mediated cell adhesion, and focal adhesion genes (Fig. 5c,
d and Supplementary Fig. 5A)
Overall these data suggest that BlackMamba is
involved in the maintenance of appropriate completion of
cytokinesis.
BlackMamba regulates the transcription of the
lymphoid-specific DNA helicase HELLS
Chromatin-enriched lncRNAs are spatially correlated with
transcription factors [31], can act as cell type-specific acti-
vators of proximal gene transcription [32] and chromatin-
associated lncRNAs (such as XIST or KCNQ1ot1) can
influence local chromatin organization, leading to in cis
transcriptional repression of genes within large genomic
regions [33].
To test whether BlackMamba could operate according to
this model, we correlated its expression with transcriptional
factors and chromatin-remodeling genes (16 ALK− ALCL
and 21 ALK+ ALCL samples). The lymphoid-specific
helicase (LSH) HELLS, the SET domain containing protein
PRDM13, and the polycomb repressive complex 2 histone-
lysine N-methyltransferase EZH2 were found to be posi-
tively correlated with BlackMamba. Conversely, the
homeobox protein HHEX showed a negative correlation
(Fig. 5e). To test whether this association was directly
linked to BlackMamba expression, we quantified the
mRNA levels of HELLS and HHEX in inducible shRNA
BlackMamba ALCL cells. HELLS expression was con-
sistently downregulated upon BlackMamba silencing, while
HHEX was upregulated (Fig. 5f and Supplementary
Fig. 5B). No consistent changes were observed for EZH2
(Supplementary Fig. 5C) while PRDM13 mRNA was
undetectable (data not shown). In line with the gene
expression changes, H3K4me3 and H3K27me3 underwent
chromatin reorganization, with a significant reduction of
H3K4me3 binding on HELLS promoter and a parallel loss
of H3K27Me3 on HHEX promoter after silencing (Fig. 5g).
Being also HHEX and HELLS the only TFs located on
the same chromosome of BlackMamba, we hypothesed that
BlackMamba could regulate gene expression in cis.
To enforce this concept, we quantified the mRNA levels
of several neighboring genes spanning 1Mb from Black-
Mamba locus. After BlackMamba KD, 5/6 genes were
concordantly downregulated in MAC2A and TLBR-2 cell
lines (Supplementary Fig. 5D).
These data support the model which predicts that
BlackMamba regulates in cis the expression of genes
located on the same chromosome.
BlackMamba interacts with HELLS to control the
BlackMamba-dependent transcriptional program
HELLS, also known as LSH or proliferation-associated
SNF2-like (PASG), belongs to a large family of SNF2
chromatin-remodeling ATPases. HELLS is critical to the
normal development and survival of lymphoid cells [34] and
regulates chromatin organization and gene expression
[35, 36]. HELLS mutations or misregulated expression were
seen in several cancers and some cases of ICF syndrome [37].
To test whether HELLS enforces BlackMamba-mediated
transcription, we silenced HELLS by specific shRNAs.
qRT-PCR and WB analyses confirmed an effective silen-
cing (Fig. 6a, b and Supplementary Fig. 6A), demonstrating
the concomitant downregulation of known target BMI-1
and MLL1 genes [38, 39] (Supplementary Fig. 6B). Inter-
estingly, the loss of HELLS was linked to expression
changes of RGS1, CCL17, CCL22, PAK2, and KCNMA1,
phenocoping the BlackMamba KD phenotype (Fig. 6c).
Fig. 5 BlackMamba regulates the lymphoid-specific helicase
HELLS. a Immunofluorescence images of TLBR-2 expressing pLKO-
shRNA#6 BlackMamba stained with antiphalloidin antibody after
doxycycline treatment (6 days). The scale bar represents 10 μm.
b Volcano plot analysis of TLBR-2 expressing pLKO-shRNAs#6
BlackMamba after 6 days of doxycycline induction. c GSEA analyses
of downregulated and upregulated pathways in TLBR-2 expressing
pLKO-shRNA#6 BlackMamba. d qRT-PCR analysis of a panel of
genes in MAC2a and TLBR-2 expressing pLKO-shRNA#6 Black-
Mamba after 6 days of doxycycline induction. e Graph shows the
expression correlation between BlackMamba and protein-coding genes
in ALK− ALCL samples. PRDM13, HELLS, and EZH2 showed
significant positive co-regulation while HHEX showed a negative co-
regulation. f qRT-PCR analysis of HELLS (6 days after doxycycline
induction) and HHEX (9 days after doxycycline induction) expression
in ALK− ALCL cell lines. Each data point represents the mean ± S.D.
(n= 3). One-tailed t-test. *p ≤ 0.05; **p ≤ 0.01. g ChIP qRT-PCR
detection of H3K4me3 and H3K27me3 antibodies on HELLS and
HHEX promoters in TLBR-2 expressing pLKO-shRNA#6 Black-
Mamba (6 days after doxycycline induction). The experiment was
representative of a triplicate. The bars represent the mean ± SEM (n=
3). **p ≤ 0.01.
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Conversely, the ectopic expression of HELLS effectively
restored the baseline expression of these genes in Black-
Mamba KD cells (Fig. 6d, e).
It is known that lncRNAs control gene expression by
recruiting chromatin-remodeling complexes to target pro-
moters or enhancers, thereby influencing histone
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modifications and chromatin accessibility [40]. Since the
chromatin-remodeling properties of HELLS can be medi-
ated by the lncRNA HOTAIR [41], we reasoned that
BlackMamba might interact with HELLS to mediate its
recruitment to target genes. To prove a direct association
between HELLS and BlackMamba, we used RNA immu-
noprecipitation [3] and showed that HELLS binds to two
distinct regions of BlackMamba at the 3′-end of the lncRNA
(Fig. 6f). No readout was seen in HELLS KD cells. Next,
we proved that HELLS was preferentially bound to target
gene promoters only in BlackMamba-positive ALK−
ALCLs independently from HELLS basal expression level
(Fig. 6g and Supplementary Fig. 6C).
Collectively, these data demonstrate that BlackMamba-
HELLS could be a part of the regulatory complex that
occupied loci to coordinate ALK− ALCL transcriptional
program.
HELLS is required for the maintenance of the
neoplastic phenotype of ALK− ALCL
To determine the contribution of HELLS and BlackMamba
in the maintenance of ALCL phenotype, we first investi-
gated the cell growth capacity of HELLS KD cells. Indeed,
the loss of HELLS led to an impaired cell growth (Fig. 7a
and Supplementary Fig. 6D), reduced duplication rate
(Fig. 7b), and clonogenicity (Fig. 7c and Supplementary
Fig. 6E), a phenotype associated with an increased number
of polynucleated cells, phenocopying the BlackMamba KD
cells (Fig. 7d and Supplementary Fig. 6F).
Next we proved that the overexpression of HELLS could
counteract the phenotype associated with the KD of
BlackMamba, as the growth impairment of TLBR-2 cells
expressing inducible shRNA against BlackMamba was
effectively rescued (Fig. 7e) a finding associated with the
mitigation of the polynucleated phenotype of the Black-
Mamba KD (Fig. 7f).
Overall, these findings demonstrate that HELLS is an
essential downstream mediator of BlackMamba and that
BlackMamba-HELLS axis represents a vulnerability of
ALCL cells.
Discussion
Although a more complete genomic annotation of
ALK− ALCL is emerging [42, 43], the mechanistic mod-
alities of action remain elusive even for known recurrent
defects [4, 42].
Here we describe a new chromatin-associated lncRNA,
named BlackMamba, preferentially expressed in ALK−
ALCL. Mechanistically, STAT3 regulates the expression of
BlackMamba and its expression is required for ALK−
ALCL neoplastic phenotype. This is achieved mainly
through the action of the LSH, HELLS (Fig. 7g) and the
transcriptional regulation of genes controlling G-protein and
cytoskeletal organization, cell migration, tissue recruitment,
and inflammation.
While emerging evidence have shown that lncRNAs are
pathogenetic in human B-cell hematological neoplasms
[44], little is known in mature T-cell neoplasms [23–25, 45].
In this study, we identified 1208 previously unknown
lncRNAs linked to normal or neoplastic T-cells and among
them, 18 lncRNAs were largely restricted to ALCL.
Accordingly, a third of these new lncRNAs were co-shared
by both ALCL subtypes, supporting the notion that both
ALK+ and ALK− ALCL can share some communalities
[46].
Deregulated activation of STAT3 is a hallmark of many
human cancers [47]. ALK+ ALCL and a subset of ALK−
ALCL have been proven to be addicted to the JAK/STAT
signaling pathway [3, 48] and BIA-ALCL display a con-
stitutive JAK/STAT deregulation [49]. Here, BIA-ALCL
cell lines, as well as PDTX, were found to express high
levels of BlackMamba. In ALCL, the deregulation/activa-
tion of JAK/STAT pathway is mediated by gene fusions,
somatic mutations [50], and loss of negative regulators
[7, 51]. These lead to a distinct transcriptional program
associated with defined pathological entities [6, 46].
LncRNAs have been also shown to be linked to STAT
signaling by modulating metabolic pathways [52] and
conversely, STAT3, controlling the expression of lncRNAs,
can regulate cell differentiation [17].
BlackMamba is a target of STAT3. Both siRNA-
mediated and pharmacological inhibitions of JAK/STAT3
pathway profoundly repressed BlackMamba expression
demonstrating its contribution in cell growth and clonal
expansion of ALCL. Interestingly, loss of the BlackMamba
Fig. 6 BlackMamba controls the recruitment of HELLS on mul-
tiple target promoters. a qRT-PCR analysis of HELLS in ALK−
ALCL cell lines expressing pLKO-shRNA#2 against HELLS (48 h
after doxycycline induction). b Western blot shows the reduction of
HELLS in cells expressing pLKO-shRNA#2 HELLS after 3 days of
doxycycline induction. c qRT-PCR analysis of a panel of genes after
2 days of doxycycline induction in TLBR-2 expressing pLKO-
shRNA#2 HELLS. Each data point represents the mean ± SEM. (n=
3). *p ≤ 0.05; **p ≤ 0.01. d qRT-PCR analysis of TLBR-2 cells co-
expressing shRNA#6 BlackMamba and pCDH-HELLS-HA vectors
(6 days after doxycycline induction). e Western blot shows the over-
expression of ectopic HELLS-HA in TLBR-2 overexpressing pLKO-
shRNA#6 BlackMamba. f RIP assay for HELLS in TLBR-2 expres-
sing pLKO-shRNA#2 HELLS (2 days). Fold enrichment is relative to
IgG (average of six independent experiments ±SEM; *p ≤ 0.05; **p ≤
0.01). g ChIP qRT-PCR detection of HELLS antibody on several
BlackMamba target gene promoters in a panel of T-cell lymphoma
lines. MLL1, PD5S4 were used as positive controls (average of six
independent experiments ±SEM; *p ≤ 0.05; **p ≤ 0.01).
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expression was linked to a unique phenotype characterized
by an increased number of polynucleated cells with a
balanced chromosomal enumeration possibly linked to key
genes regulating cytoskeleton and cell motility. As STAT3
can regulate cell migration via RAC1 and Rho [53, 54], our
data provide a new layer of complexity demonstrating a
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new role for STAT3 in cell shape and cytoplasmic partition
via the axis of BlackMamba-HELLS. This model is sup-
ported by phenotype seen in HELLS KD cells, arguing that
HELLS represents a critical downstream effector of
BlackMamba.
Mechanistically, BlackMamba also contributes to the
neoplastic phenotype of ALCL via multiple mediators,
modulating a large group of genes encoding chemokines
and chemokine receptors (CCL17–22 and CXCL10), G-
protein regulators (RGS1) and multiple proteins involved in
cell growth and motility (PAK2, ERBB2, RHOU, KIF21b).
Among BlackMamba targets, we found HELLS
(16,550,000 bp from the locus of BlackMamba). HELLS
controls T-cell growth [34], regulates DNA methylation
[55], and modulates the epigenetic states at specific
enhancers of key cell cycle regulators [56]. In cancer cells,
HELLS sustains glioma stemness and through the interac-
tion with E2F3 controls cell proliferation of prostate cancer
cells [38, 57]. By interacting with the epigenetic silencer
factor G9a, HELLS represses gene transcription [58].
Remarkably, a recent genome-scale CRISPR-Cas9 screen
has shown cancer dependencies to DNA helicase and
identified ATP-DNA helicases as promising new synthetic
lethal targets in tumors [59]. Our work extends these find-
ings providing a new lncRNA-dependent mechanism con-
trolling the recruitment of HELLS on chromatin sites and its
expression in lymphomas.
Our data provide novel insights into the transformation
of ALCL via the untapped role of a lncRNA. Collectively,
the findings further support the design of target therapeutic
strategies to pharmacologically ablate/inhibit the expression
of STAT3 and encourages novel discovery programs for the
selection of compounds which could impair STAT3-
downstream effector elements like HELLS. Lastly, since
HELLS is expressed in many human tumors and plays a
relevant role in DNA repair and genomic stability of
cancers, its pharmacological inhibition represents a viable
therapeutic strategy in many human cancers.
Data availability
BlackMamba sequence has been deposited in GenBank
database with the accession number MN902222.
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